Novartis
healthcare [Zuellig]
C: Hydralazine HCL.
I: Listed in dosage.
D: Tab hypertension adult initially, 25mgBID. Maintenance: 50-200mg daily. (for doses 100mg daily, first determine patient’s acetylator phenotype). Childn initially 0.75 mg/kg body wt. Daily. Max 3.5 mg/kg body wt. Daily. Chronic CHF adult maintenance: 50-75mg 6 hrly or 100mgBID-TID. Childn initially 0.75-1 mg/kg body wt in 4 divided dosage given 6 hrly gradually increasing to 4 mg/ kg body wt daily. AMP hypertensive crisis adult slow IV: initially, 5-10mg, repeat after 20-20min. if necessary. Continuous IV infusion:initially 200-300mug/min, maintenance: 50 –150 ug/ min. childn initially 0.1-0.5mg/kg body wt. IV over 1-2min, repeat every 30-90 min as required. Max:3.5 mg/kg body wt/day.
CI: Idiopathic SLE & related disease, Severe tachycardia &heart failure w/ high cardiacoutput. Myocardial insufficiency due to mechanical obstruction. Isolated right ventricular heart failure due to pulmonary hypertension. Amp dissecting aortic aneurysm.
SP: coronary artery disease. Recent MI. renal & hepatic dysfunction, acute cerebrovascular disease, surgery. Pregnancy, lactation. Prolonged treatment. May impair ability to drive or operate machinery.
AR: tachycardia, palpitations, flushing, anginal symptoms, hypotension, heart failure; GI disturbances;rarely, hemolytic anemia, agranulocytosis, hepatitis, renal failure, glomerulonephritis, SLE- like symdrome, arthralgia, joint swellingheadache.
DI: BP lowering effect may be potentiated by concurrent use of anesth. Other antihypertensives, major tranquilizers, tricyclic antidepressants. Decrease antihypertensive effect. When used concomitantly w/ sympathomimetics, tricyclic antidepressants. Administration shortly before or after diazoxide.MAOIs blockers.
P/P: Tab 10 mg x 100’s (P724.19), 500’s (P3,195.89), 25mg x 100’s (P1,239.32), 500’s (P5,965.58). 50mgx 100’s (P2,202.20). amp 20 mg/2 ml x 50’s (P3,430.35).
